Exhibit 99.1


                   Human BioSystems Appoints A New President


Palo Alto, CA - August 30, 2005 - (OTCBB:HBSC)-Human Biosystems announces today
the appointment of Dr. David Winter its new President. Harry Masuda, who has
held the positions of President and CEO since the Company's inception, will
continue as its CEO.

"I am very pleased to welcome Dr. Winter to HBS," said Harry Masuda. "His
experience and knowledge in both the science and the operations side of managing
medical technology companies will greatly benefit HBS, especially at this stage
of our history," continued Mr. Masuda.  He went on to say, "Dr. Winter, who
served on our Advisory Board, will now play a more active role in directing HBS
as President, by guiding us through the regulatory process including FDA trials
when required, and leading HBS through negotiations with potential alliance
partners.

Dr. Winter has over 20 years experience in the pharmaceutical industry. He held
the positions of President and COO of GenPharm International, SangStat Medical
Corp., President and CEO of Human Organ Sciences and most recently with TriMed
research, Inc., as its CEO.

Dr. Winter is an experienced physician with a strong background in managing the
clinical development and approval process. He served as President of the Sandoz
Research Institute and as Vice President of Clinical Research and Development
for Sandoz Pharmaceuticals. He led the development, registration and approval of
cyclosporin as well as six other major compounds.

Prior to his industrial experience, Dr. Winter was the NASA Director of Life
Sciences. In this position, he directed all the medical, biological, and
biomedical-engineering activities for the US space program. He received his MD
from Washington University School of Medicine in St. Louis.

"I am very excited to be part of Human BioSystems and to be in a position to
help shape the future of the Company," said Dr. David Winter.

HBS is headquartered in Palo Alto, California with research facilities in
Michigan.

For further information about this release and the Company, contact Harry
Masuda, President, Human BioSystems, # 650-323-0943, hmasuda@
humanbiosystems.com  and/or contact Rich Kaiser, Investor Relations, YES
INTERNATIONAL, 800-631-8127, yes@yesinternational.com.

Certain statements contained herein are "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995).
Because such statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements. Factors that could cause results to differ materially from those
expressed or implied by such forward-looking statements include, but are not
limited to, results from ongoing research and development as well as clinical
studies, failure to obtain regulatory approval for the Company's products, if
required, failure to develop a product based on the Company's technology,
failure of any such products to compete effectively with existing products, the
ability of the Company to fund marketing and sales efforts that may be required
to effectively sell its products .and other factors discussed in filings made by
the Company with the Securities and Exchange Commission